Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||TP53 P72R|
|Therapy||Cyclophosphamide + Epirubicin + Fluorouracil|
|Indication/Tumor Type||breast cancer|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 P72R||breast cancer||predicted - sensitive||Cyclophosphamide + Epirubicin + Fluorouracil||Phase I||Actionable||In a Phase I trial, breast cancer patients harboring TP53 P72R were reported to have a better response to anthracycline-based neoadjuvant therapies, including Ellence (epirubicin) in combination with Cytoxan (cyclophosphamide) and Adrucil (fluorouracil) (PMID: 16243804).||16243804|
|PubMed Id||Reference Title||Details|
|(16243804)||p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.||Full reference...|